Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 5/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1654121 | 0.87 | ACKR3 (0.46) | ACKR3TLR8USP2SMN1; SMN2STS | |
| SCHEMBL39764 | 0.82 | ACKR3 (0.50) | ACKR3TLR8USP2SMN1; SMN2CHRM2 | |
| SCHEMBL8242595 | 0.81 | USP2 (0.61) | ACKR3TLR8USP2SMN1; SMN2CHRM2 | |
| SCHEMBL1547255 | 0.81 | ACKR3 (0.44) | ACKR3TLR8USP2SMN1; SMN2STS | |
| SCHEMBL28385131 | 0.81 | ACKR3 (0.49) | ACKR3TLR8USP2SMN1; SMN2CHRM2 | |
| SCHEMBL309615 | 0.81 | USP2 (0.46) | ACKR3TLR8USP2SMN1; SMN2STS | |
| SCHEMBL14768742 | 0.81 | ACKR3 (0.49) | ACKR3TLR8USP2SMN1; SMN2CHRM2 | |
| SCHEMBL15259105 | 0.79 | ACKR3 (0.54) | ACKR3TLR8USP2SMN1; SMN2CHRM2 | |
| SCHEMBL12204590 | 0.79 | MEN1 (0.64) | ACKR3SMN1; SMN2STSMEN1KMT2A | |
| SCHEMBL19816644 | 0.79 | NR1H2 (0.42) | STSCHRM2CHRM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964654-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002273-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-01-07 | — | — | US | disclosed |
| US-20160002273-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-01-07 | — | — | US | disclosed |
| US-20160002273-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-01-07 | — | — | US | disclosed |
| WO-2014138562-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-09-12 | — | — | WO | disclosed |
| CN-101370799-B | Cis-4, 5-diaryl-2-heterocycle-imidazolines as MDM2 inhibitors | HOFFMANN LA ROCHE | 2012-09-05 | — | — | CN | disclosed |
| US-7964724-B2 | Chiral cis-imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7705007-B2 | Cis-imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7579368-B2 | Cis-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090143364-A1 | CHIRAL CIS-IMIDAZOLINES | FOTOUHI NADER | 2009-06-04 | — | — | US | disclosed |
| CN-101370799-A | Cis-4, 5-diaryl-2-heterocycle-imidazolines as MDM2 inhibitors | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | CN | disclosed |
| EP-1753727-B1 | NOVEL CIS-IMIDAZOLINES | HOFFMANN LA ROCHE (CH) | 2008-11-19 | — | — | EP | disclosed |
| EP-1861376-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F. Hoffmann-Roche AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| US-20070167437-A1 | Cis-imidazolines | FOTOUHI NADER | 2007-07-19 | — | — | US | disclosed |
| EP-1753727-A1 | NOVEL CIS-IMIDAZOLINES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006097261-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211693-A1 | Cis-imidazolines | FOTOUHI NADER | 2006-09-21 | — | — | US | disclosed |
| US-20050288287-A1 | Chiral cis-imidazolines | FOTOUHI NADER | 2005-12-29 | — | — | US | disclosed |
| WO-2005110996-A1 | NOVEL CIS-IMIDAZOLINES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211693-A1 | Cis-imidazolines | TP53, MDM2, CDC25C | ACKR3 2041/4885TLR8 4679/4885USP2 1372/4885 |
| US-20160002273-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT2, SIRT1, SIRT6 | ACKR3 3717/4885TLR8 1005/4885USP2 2305/4885 |
| US-20090143364-A1 | CHIRAL CIS-IMIDAZOLINES | TP53, MDM2, TP53BP1 | ACKR3 470/4885TLR8 4729/4885USP2 670/4885 |
| US-20050288287-A1 | Chiral cis-imidazolines | TP53, MDM2, TP53BP1 | ACKR3 470/4885TLR8 4729/4885USP2 670/4885 |
| US-20070167437-A1 | Cis-imidazolines | CCNI, CCNE1, CCNA1 | ACKR3 3274/4885TLR8 4535/4885USP2 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.